Vedanta Biosciences, Inc.
Cambridge, MA
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 19 Blackstone St, Cambridge, MA 02139, USA
- Website
- vedantabio.com
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $18,000,000 |
| FY2024 | $25,000,000 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| To develop medical countermeasures (MCMS) that treat antibiotic resistant infections. | Office of the Assistant Secretary for Preparedness and Response | $79,146,088 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $2,601,928 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Lumen Bioscience, Inc. | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Siolta Therapeutics Inc. | San Carlos, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Crestone, Inc. | Boulder, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Biomesense Inc. | Chicago, IL | — |
| Osel, Inc. | Mountain View, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Vedanta Biosciences is a biotechnology company that pioneers the rational design of drugs made of defined consortia of bacteria found in the gut ecosystem. It is registered in SAM.gov as a for-profit corporate entity eligible to receive federal awards.
Through prime federal contract awards, Vedanta Biosciences has been tasked with developing medical countermeasures to treat antibiotic resistant infections. Notably, it received a contract potentially worth over $104 million from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to advance its live biotherapeutic product VE303 through clinical development for the prevention of recurrent Clostridium difficile infection. The contract aims to counter biological and pandemic threats, with no set-aside designation applied. It also has a sub-contract award from Boston University to develop an orally administered investigational live biotherapeutic product (VE707) consisting of defined, well-characterized, beneficial gut bacteria to decolonize gut-dwelling multidrug-resistant organisms (MDROs) like carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE) in high-risk patients to prevent infections and restore a healthy microbiota.
Through a sub-grant award from Boston University, Vedanta Biosciences is working on developing VE707, an investigational live biotherapeutic product consisting of defined gut bacteria, to eliminate intestinal carriage of CRE, ESBL, and VRE to prevent infections with these MDROs, restore a healthy microbiota, and prevent colonization recurrence. The grant aims to address the critical need for novel therapeutics to prevent MDRO infections, which can result in life-threatening treatment delays, death, and approximately $2 billion in healthcare-associated costs due to patient isolation practices alone.
Quick answers
Is Vedanta Biosciences, Inc. registered in SAM.gov?
Yes. Vedanta Biosciences, Inc.'s SAM.gov registration is active through September 23, 2027.
What is Vedanta Biosciences, Inc.'s CAGE code?
Vedanta Biosciences, Inc.'s CAGE code is 6DGY3, and its Unique Entity ID (UEI) is C91JJXT9QND5.
How much has Vedanta Biosciences, Inc. received in federal contracts?
Federal contracts obligated $18,000,000 to Vedanta Biosciences, Inc. in fiscal year 2025 and $43,000,000 in fiscal years 2023 through 2027.
How does Vedanta Biosciences, Inc. rank among federal contractors?
Vedanta Biosciences, Inc. ranked #6 in PSC AZ and #28 in NAICS 541714 in FY2025.
What is Vedanta Biosciences, Inc.'s most recent federal award?
Vedanta Biosciences, Inc.'s most recent federal contract award is To develop medical countermeasures (MCMS) that treat antibiotic resistant infections (75A50120C00177), from Office of the Assistant Secretary for Preparedness and Response, on September 28, 2020.
On GovTribe
See Vedanta Biosciences, Inc.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors